Compare NetEase Inc (NTES) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs GeneDx Holdings Corp — how do they compare? NetEase Inc trades at $116.22 (market cap $74.79B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: NetEase Inc is far larger — about 29× GeneDx Holdings Corp's market cap, and NetEase Inc pays a 2.53% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| NTES | WGS | |
|---|---|---|
Market Cap | $74.79B | $2.58B |
Sector | Media | Technology |
52-Week High | $159.34 | $167.51 |
52-Week Low | $109.26 | $34.51 |
Enterprise Value | $50.53B | $2.61B |
Dividend Yield | 2.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTES trades at $119.45, up 0.13% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $1.77, missing expectations of $2.32, though revenue grew 8% year-over-year to $4.4 billion. Strong fundamentals include a 27.88% net income margin and $137.58 billion in cash, supporting dividend growth and AI investments.
Outlook is mixed: analyst consensus is strongly bullish (82% buy ratings), citing undervaluation and international expansion potential, but near-term risks include earnings volatility and competitive pressures in gaming. The stock offers value at a P/E of 15.93, yet technical weakness suggests cautious entry points near support at $117.
WGS trades at $85.87, down 0.14% on the day, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4 million, beating estimates, and achieved adjusted profitability ahead of schedule. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics, driving positive sentiment.
Outlook is cautiously optimistic due to strong analyst support (90.9% buy ratings) and revenue growth, but risks include negative net income margins, high valuation multiples, and ongoing class action lawsuits. The stock's upside potential hinges on sustained operational improvements and market expansion in genomics diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
